本文選題：非小細(xì)胞肺癌 + ctDNA　； 參考：《實用醫(yī)學(xué)雜志》2017年19期

【摘要】：目的采用液體活檢技術(shù)檢測171例NSCLC患者外周血ct DNA樣本中EGFR-T790M的突變情況,并結(jié)合其臨床病理特征進(jìn)行分析。方法采用超級擴(kuò)增阻礙突變系統(tǒng)(super ARMS)法檢測171例樣本中EGFR-T790M的突變情況。結(jié)果在171例樣本中T790M基因的突變率為7.60%(13/171),且多數(shù)為Ⅲb~Ⅳ期的肺癌患者。未經(jīng)TKIs治療樣本的T790M突變率為2.05%(3/146)明顯低于經(jīng)TKIs治療后樣本的突變率40.00%(10/25,P0.001)。服用第一代TKI藥物時間在6~10個月或10個月樣本的T790M突變率分別為75.00%(3/4)和60.00%(6/10)明顯高于服藥時間6個月的T790M突變率9.10%(1/11,P=0.033,P=0.023)。結(jié)論 EGFR-T790M基因突變多見于有TKI用藥史且服藥時間6個月的晚期NSCLC患者,動態(tài)檢測EGFR-T790M的突變狀態(tài)可有效指導(dǎo)臨床的用藥。
[Abstract]:Objective to detect the mutation of EGFR-T790M in peripheral blood ct DNA samples of 171 patients with NSCLC by liquid biopsy and analyze its clinicopathological features. Methods the mutation of EGFR-T790M in 171 samples was detected by super Amplification hindering mutation system (ARMS). Results the mutation rate of T790M gene in 171 samples was 7.600.13 / 171%, and most of them were stage 鈪，

本文編號：1815531